Preclinical data from lead program addressing AURIGIN-identified KAT2A/B target showed significant cell state shift and tumor growth inhibition across multiple primary cancer models AURIGIN overview highlighted capability to identify key drivers of dysregulated cell states in cancer Data support advancement of AUTX-703 toward planned IND submission in late 2024 NEWTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting.

来自解决AURIGIN确定的KAT2A/B靶标的领导计划的临床前数据显示，在多种原发性癌症模型中，细胞状态发生了显着变化，肿瘤生长受到抑制AURIGIN概述强调了识别癌症中细胞状态失调的关键驱动因素的能力数据支持AUTX-703在2024年下半年向计划的IND提交取得进展。牛顿，马萨诸塞州，2024年4月9日（环球通讯社）——Auron Therapeutics是一家生物技术公司，专注于通过识别和抑制癌症的致癌细胞状态来开发下一代靶向治疗，今天在美国癌症研究协会（AACR）年会上宣布了两张海报。

The Company highlighted the distinct ability of its AURIGIN™ platform to identify both cell state plasticity, the proliferative state in which cancer cells grow, and the causative gene targets. In a second poster, Auron shared preclinical data from its program targeting KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML).

该公司强调了其AURIGIN™平台识别细胞状态可塑性，癌细胞生长的增殖状态和致病基因靶标的独特能力。在第二张海报中，Auron分享了其针对KAT2A/B的计划的临床前数据，该计划是一种AURIGIN鉴定的组蛋白乙酰转移酶，可驱动小细胞肺癌（SCLC），神经内分泌前列腺癌（NEPC）和急性髓性白血病（AML）。

These data led to the nomination of AUTX-703, an orally available and selective KAT2A/B degrader development candidate, for which Auron expects to file an IND in 2024. “Our AACR presentations highlight the unique capability of our AURIGIN platform to identify critical drivers of cancer cell state and translate that knowledge into a comprehensive development program that targets the drivers for an anti-tumor effect,” said Kate Yen, Ph.D., Founder and Chief Executive Officer of Auron.

这些数据导致了AUTX-703的提名，AUTX-703是一种口服和选择性KAT2A/B降解剂开发候选人，Auron预计将于2024年提交IND。Auron创始人兼首席执行官Kate Yen博士说：“我们的AACR演讲突出了AURIGIN平台的独特能力，它可以识别癌细胞状态的关键驱动因素，并将这些知识转化为针对抗肿瘤作用驱动因素的综合发展计划。”。

“Using AURIGIN, we identified that KAT2A/B was responsible for driving growth and proliferation of SCLC, NEPC and AML. Also with AURIGIN, we designed novel small molecule degra.

“使用AURIGIN，我们发现KAT2A/B负责驱动SCLC，NEPC和AML的生长和增殖。此外，我们还使用AURIGIN设计了新型小分子降解物。